Cellular Therapy involves utilization of cells for treatment including haematopoietic stem cell transplantation (HSCT). HSCT may enable stem and progenitor cells to be engrafted, replacing the bone marrow of the recipient completely. Other examples include bone marrow-derived mesenchymal stromal cells, embryonic or induced pluripotent stem cells (iPs) and specific T-lymphocytic cell lines which can differentiate into a variety of cells. In the future this might also include the ex-vivo expansion of cord blood into red blood cells, platelets and their progenitors. Novel blood-derived therapeutics include platelet lysates, amniopatch and serum eye drops.
We cover all the different aspects of (novel) cellular therapies. We foster collaboration amongst ISBT members, promote investigation and initiate projects including guidelines and standards. We act as an expert group to advise ISBT and cooperate with the AABB Cell therapy Working Group. We provide a platform for discussion, especially when related to transfusion and provide a resource for learning and the exchange of ideas.
Our Chairperson is Mickey Koh.
We meet at the ISBT congresses and initiate collaborative projects. We advise and represent ISBT on global issues regarding cellular therapy and collaborate with AABB's Cellular Therapy Group.
Our WP currently comprises mostly of medical professionals including haemato-oncologists, infectious disease experts, doctors, nurses and scientists working in the area of cell and tissue regeneration. But other interested individuals (regulatory affairs, specialized nurses, quality managers or scientists) are also eligible to join.
Interested in joining the Cellular Therapies WP? Please email our Chairperson.
Some of the content is only accessible for ISBT-members.
To join us, click here.
Our main aim is to bring current and best practices in cellular therapy to transfusion professionals. Please find below some topics where we work on supporting you with material and ideas. Please click on the below links to read more about the Working Party activities.
- Current methods to manufacture human platelet lysates for cell therapy and tissue engineering: possible trends in product safety and standardizationISBT Science Series
- A double-virally-inactivated (Intercept–solvent/detergent) human platelet lysate for in vitro expansion of human mesenchymal stromal cells Transfusion
- Four types of human platelet lysate, including one virally inactivated by solvent-detergent, can be used to propagate Wharton jelly mesenchymal stromal cellsNew Biotechnology
- The protective effect of human platelet lysate in models of neurodegenerative disease: involvement of the Akt and MEK pathways Tissue Engineering and Regenerative Medicine
- International Forum on GMP-grade human platelet lysate for cell propagation: summaryVox Sanguinis
- Multifaceted regenerative lives of ‘expired’ plateletsISBT Science Series
- Preparation, quality criteria, and properties of human blood platelet lysate supplements for ex vivo stem cell expansionNew Technology
- Removal of Transmissible Spongiform Encephalopathy Prion from Large Volumes of Cell Culture Media Supplemented with Fetal Bovine Serum by Using Hollow Fiber Anion-Exchange Membrane Chromatography Plos One
- Human platelet lysate current standards and future developmentsTransfusion
- Tailor-made purified human platelet lysate concentrated in neurotrophins for treatment of Parkinson's diseaseBiomaterials
- The use of platelets in regenerative medicine and proposal for a new classification system: guidance from the SSC of the ISTHJournal of Thrombosis and Haemostasis
- Removal process of prion and parvovirus from human platelet lysates used as clinical-grade supplement for ex vivo cell expansionCytotherapy
- Animal models to assess the therapeutic efficacy of human serum and serum-converted platelet lysates for dry eye syndrome: Seeing is believingTransfusion and Apheresis Science
- Reflections on Dry eye Syndrome Treatment: Therapeutic Role of Blood Products Frontiers in Medicine
- Solvent/Detergent Virally Inactivated Serum Eye Drops Restore Healthy Ocular Epithelium in a Rabbit Model of Dry-Eye SyndromePlos One
Eye Drops from Human Origin - First EDHO Workshop on Current Standards and Future Developments March 19-20, 2020 is postponed and will be held on March 25 and 26, 2021 in Vienna, Austria.